T-DXd in Patients with High-Risk HER2-Positive Early Breast Cancer – Are We Ready to Change Practice?

Interview: Positive results from DESTINY-Breast11 and DESTINY-Breast05 highlight the potential of T-DXd in early HER2-positive breast cancer – but also raise important questions about optimal use in clinical practice, says Henrik Lindman, Professor of Oncology at Uppsala University Hospital, Sweden.